Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPAL-BROADEN
  • Sponsors Pfizer

Most Recent Events

  • 15 Nov 2023 Results of pooled post hoc analysis data from (NCT01877668 and NCT01882439) assessing variations by identifying pt groups with distinct disease activity trajectories; comparisons of associated baseline (BL) variables across groups were used to describe clinical phenotypes in pts with PsA treated with tofacitinib were presented at the ACR Convergence 2023.
  • 22 Aug 2023 Results of pooled post hoc analysis data from (NCT01877668/NCT01882439) tofacitinib efficacy on enthesitis by baseline location and severity, and impact on disease activity and patient-reported outcomes (PROs), in patients with PsA published in the Arthritis Research and Therapy
  • 03 Jun 2023 Results of pooled data from (NCT01877668/NCT01882439/NCT03486457/NCT01976364) assessing ong-term safety/efficacy of tofacitinib in TNFi-inadequate responder (IR) and biologic disease-modifying antirheumatic drug (bDMARD)-naive PsA pts presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top